The Future of Palbociclib for the Treatment of Breast Cancer

Richard Finn, MD
Published Online: June 19, 2013


Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.

Currently, palbociclib is the lead indication in patients with ER-positive breast cancer, Finn says, and could become a practice-changing agent.

If the magnitude of progression-free survival benefit seen in the phase II study of this agent is seen in the phase III study, palbociclib will become the standard of care for first-line ER-positive disease, Finn notes. Palbociclib is well-tolerated, as is any anti-endocrine therapy.

If the efficacy of palbociclib can be improved without a significant increase in toxicity, the door for palbociclib would be open to other settings, Finn says. Palbociclib could be evaluated in other lines of therapy and other subtypes of breast cancer. The ultimate objective, Finn says, is to get palbociclib to early-stage disease.

Clinical Pearls



  • Finn believes palbociclib will be a practice-changing agent for the treatment of ER-positive breast cancer
  • Palbociclib demonstrated benefit to progression-free survival in this population compared with letrozole
  • In the future, palbociclib could move to other lines of therapy and subtypes of breast cancer


<<< View all coverage from the 2013 ASCO Meeting

Related Articles
Targeted therapies, including TKIs, are increasingly being investigated in head and neck cancers, including RM-SCCHN and advanced thyroid cancers.
A New Drug Application has been submitted to the FDA for palbociclib plus letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer.
Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses the possibility of using endocrine resistance therapy to treat patients with early stage breast cancer.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
JTT Articles
Immunotherapies in CRPC: Progress Evident but Not Without Challenges
Targeting Radiotherapy in the Liver: SIR-Spheres®
Searching for Positives in Triple-Negative Breast Cancer
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.